BVF INC IL's Q3 2026 13F: 4 new positions, 1 exit

Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 47 reported positions · accession 0000921895-26-003162

What changed this quarter

BVF INC IL's changes in reported equity positions, Q3 2026
Activity Security Weight before Weight now Change Shares Shares %
Exited XOMA ROYALTY CORPORATION (XOMA) 8.3% — −8.3 pts −7.59M sh −100%
Reduced REVOLUTION MEDICINES INC (RVMD) 14.2% 16.6% +2.4 pts −505K sh −17%
Reduced DISC MEDICINE INC (IRON) 2.2% 0.5% −1.7 pts −920K sh −80%
Increased TYRA BIOSCIENCES INC (TYRA) 1.2% 3.0% +1.8 pts +2.74M sh +186%
Reduced MIRUM PHARMACEUTICALS INC (MIRM) 3.2% 1.1% −2.0 pts −649K sh −61%
Increased ENTERA BIO LTD (ENTX) 0.1% 1.6% +1.5 pts +14.63M sh +603%
Increased ALKERMES PLC (ALKS) 2.9% 3.8% +0.9 pts +692K sh +32%
Increased STOKE THERAPEUTICS INC (STOK) 2.1% 3.1% +1.0 pts +1.06M sh +42%
New PYXIS ONCOLOGY INC (PYXS) — 0.9% +0.9 pts +11.83M sh new
Reduced XENCOR INC (XNCR) 2.9% 5.1% +2.2 pts −907K sh −13%
Reduced STRUCTURE THERAPEUTICS INC (GPCR) 4.6% 2.8% −1.9 pts −675K sh −20%
Reduced KURA ONCOLOGY INC (KURA) 2.4% 2.4% 0.0 pts −1.76M sh −21%
New ALECTOR INC (ALEC) — 0.6% +0.6 pts +10.05M sh new
Reduced AVALO THERAPEUTICS INC (AVTX) 1.0% 0.5% −0.5 pts −1.17M sh −56%
Reduced NEKTAR THERAPEUTICS (NKTR) 4.3% 4.2% 0.0 pts −257K sh −11%
Increased SAGIMET BIOSCIENCES INC (SGMT) 0.5% 1.1% +0.6 pts +1M sh +40%
Reduced PALVELLA THERAPEUTICS INC NE (PVLA) 2.6% 2.8% +0.1 pts −65,640 sh −10%
New TCGX ACQUISITION CORP (TCGX) — 0.2% +0.2 pts +500K sh new
New RESEARCH ALLIANCE CORP IV (RACD) — 0.2% +0.2 pts +500K sh new
Increased CRESCENT BIOPHARMA INC. (CBIO) 1.3% 1.5% +0.2 pts +345K sh +13%
Reduced ZYMEWORKS INC (ZYME) 2.4% 3.0% +0.6 pts −185K sh −5%
Increased ONKURE THERAPEUTICS INC (OKUR) 0.4% 0.4% 0.0 pts +810K sh +25%
Reduced MONTE ROSA THERAPEUTICS INC (GLUE) 2.8% 1.7% −1.1 pts −184K sh −4%
Reduced IMMUNOCORE HLDGS PLC (IMCR) 1.1% 1.2% +0.2 pts −63,554 sh −5%
Reduced X4 PHARMACEUTICALS INC (XFOR) 0.3% 0.2% −0.1 pts −657K sh −29%
Reduced ANNEXON INC (ANNX) 1.3% 1.2% −0.1 pts −420K sh −5%
Reduced TENAX THERAPEUTICS INC (TENX) 0.1% 0.0% −0.1 pts −315K sh −93%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 66.0% of the equity book

Changes in the top 10 this quarter: STOK entered · TYRA entered · ZYME entered · XOMA left · GPCR left · MIRM left

# Security Weight before Weight now
1 REVOLUTION MEDICINES INC (RVMD) 14.2% 16.6%
2 KYMERA THERAPEUTICS INC (KYMR) 11.4% 14.2%
3 GH RESEARCH PLC (GHRS) 5.9% 6.7%
4 MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 8.0% 6.2%
5 XENCOR INC (XNCR) 2.9% 5.1%
6 NEKTAR THERAPEUTICS (NKTR) 4.3% 4.2%
7 ALKERMES PLC (ALKS) 2.9% 3.8%
8 STOKE THERAPEUTICS INC (STOK) 2.1% 3.1% Entered the top 10
9 TYRA BIOSCIENCES INC (TYRA) 1.2% 3.0% Entered the top 10
10 ZYMEWORKS INC (ZYME) 2.4% 3.0% Entered the top 10
— XOMA ROYALTY CORPORATION (XOMA) 8.3% 0.0% Left the top 10
— STRUCTURE THERAPEUTICS INC (GPCR) 4.6% 2.8% Left the top 10
— MIRUM PHARMACEUTICALS INC (MIRM) 3.2% 1.1% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).